• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Dyadic International Inc. (Amendment)

    2/14/22 5:22:40 PM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $DYAI alert in real time by email
    SC 13G/A 1 emalf20220209_sc13ga.htm SCHEDULE 13G/A emalf20220209_sc13ga.htm
     

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    ____________________________________________

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

    DYADIC INTERNATIONAL, INC.


    (Name of Issuer)

     

    Common Stock, $0.001 par value


    (Title of Class of Securities)

     

    26745T101


    (CUSIP Number)

     

    December 31, 2021


    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)

     

    ☐ Rule 13d-1(c)

     

    ☒ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    Page 1 of 6

     

     

    CUSIP No. 26745T101

    (1)

    NAMES OF REPORTING PERSONS

    Mark A. Emalfarb

    (2)

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
    (a) ☐
    (b) ☐

    (3)

    SEC USE ONLY

     

    (4)

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States of America

    Number of
    Shares

    (5)

    SOLE VOTING POWER

    5,164,015 (1)

    Beneficially

    Owned

    (6)

    SHARED VOTING POWER

    0

    by Each
    Reporting

    (7)

    SOLE DISPOSITIVE POWER

    5,164,015 (1)

    Person With:

    (8)

    SHARED DISPOSITIVE POWER

    0

    (9)

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    5,164,015 (1)

    (10)

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    ☐

    (11)

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    17.9%

    (12)

    TYPE OF REPORTING PERSON

    IN

     

    (1) See Item 4 herein.

     

    Page 2 of 6

     

     

     

    Item 1

    (a)

    Name of issuer:

         
       

    Dyadic International, Inc.

         

     

    (b)

    Address of issuer’s principal executive offices:

         
       

    140 Intracoastal Pointe Drive

       

    Suite 404

       

    Jupiter, Florida 33477

         

    Item 2

    (a)

    Name of person filing:

         
       

    Mark A. Emalfarb

         

     

    (b)

    Address or principal business office or, if none, residence:

         
       

    140 Intracoastal Pointe Drive

       

    Suite 404

       

    Jupiter, Florida 33477

         

     

    (c)

    Citizenship:

         
       

    United States of America

         

     

    (d)

    Title of class of securities:

         
       

    Common Stock, $0.001 par value

         

     

    (e)

    CUSIP No.:

         
       

    26745T101

     

    Page 3 of 6

     

     

     

    Item 3

    If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

       

     

    (a)

    ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

         

     

    (b)

    ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

         

     

    (c)

    ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

         

     

    (d)

    ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);

         

     

    (e)

    ☐ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

         

     

    (f)

    ☐ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

         

     

    (g)

    ☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

         

     

    (h)

    ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

         

     

    (i)

    ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

         

     

    (j)

    ☐ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

         

     

    (k)

    ☐ Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

     

       
        Not applicable.
         

    Item 4

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

         

     

    (a)

    Amount beneficially owned:

         
       

    5,164,015 (1)

         

     

    (b)

    Percent of class:

         
       

    17.9%

     

    Page 4 of 6

     

     

     

     

    (c)

    Number of shares as to which the person has:

         
       

    (i)

    Sole power to vote or direct the vote

           
         

    5,164,015 (1)

           
       

    (ii)

    Shared power to vote or direct the vote

           
         

    0

           
       

    (iii)

    Sole power to dispose or to direct the disposition of

           
         

    5,164,015 (1)

           
        (iv)

    Shared power to dispose or to direct the disposition of

           
       

     

    0
           
      (1) The reporting person beneficially owns 5,164,015 shares through the Mark A. Emalfarb Trust U/A/D October 1, 1987, of which the reporting person is the sole beneficiary and serves as sole trustee. Includes 770,000 shares issuable upon the exercise of options presently exercisable.

     

    Item 5

    Ownership of 5 Percent or Less of a Class.

     

    Not applicable.

     

    Item 6

    Ownership of More than 5 Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8

    Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9

    Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10

    Certifications.

     

    Not applicable.

     

    Page 5 of 6

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2022

     

      /s /  Mark A. Emalfarb         
             Mark A. Emalfarb

     

    Page 6 of 6
    Get the next $DYAI alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $DYAI

    DatePrice TargetRatingAnalyst
    7/18/2022Buy → Neutral
    Dawson James
    12/17/2021$7.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $DYAI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Dyadic International downgraded by Dawson James

      Dawson James downgraded Dyadic International from Buy to Neutral

      7/18/22 9:59:51 AM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HC Wainwright & Co. initiated coverage on Dyadic International with a new price target

      HC Wainwright & Co. initiated coverage of Dyadic International with a rating of Buy and set a new price target of $7.00

      12/17/21 6:17:22 AM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DYAI
    SEC Filings

    See more
    • Dyadic International Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - DYADIC INTERNATIONAL INC (0001213809) (Filer)

      7/2/25 4:17:44 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Dyadic International Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - DYADIC INTERNATIONAL INC (0001213809) (Filer)

      6/27/25 4:00:16 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Dyadic International Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - DYADIC INTERNATIONAL INC (0001213809) (Filer)

      6/24/25 4:34:45 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DYAI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Tarnok Michael P. converted options into 10,776 shares, increasing direct ownership by 4% to 281,033 units (SEC Form 4)

      4 - DYADIC INTERNATIONAL INC (0001213809) (Issuer)

      6/24/25 10:34:28 AM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Bose Arindam converted options into 10,776 shares, increasing direct ownership by 21% to 61,535 units (SEC Form 4)

      4 - DYADIC INTERNATIONAL INC (0001213809) (Issuer)

      6/24/25 10:34:02 AM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by President and COO Hazelton Joseph P

      4 - DYADIC INTERNATIONAL INC (0001213809) (Issuer)

      6/6/25 11:16:59 AM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DYAI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Dyadic International, Inc. Announces Strategic Rebrand to Dyadic Applied BioSolutions

      Reflects the Company's strategic focus on commercializing non-therapeutic proteins and unlocking long-term value from its C1 and Dapibus™ gene expression platforms Dyadic International, Inc. ("Dyadic") (NASDAQ:DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered input proteins for non-therapeutic applications in life sciences, food and nutrition, and industrial biotechnology utilizing its proprietary gene expression platforms, today announced that, effective in 30 days, it will be doing business as Dyadic Applied BioSolutions, marking a pivotal step in the company's transition from a research-driven organization to a commercially foc

      7/2/25 4:00:00 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Dyadic Announces Leadership Change as Part of Ongoing Strategic Shift to Focus on High Demand Ancillary Proteins for Life Sciences, Nutrition, and Industrial Applications

      Rapid commercial validation has been achieved through key partnerships disrupting high value/high growth marketsLeadership team realigned in order to enable execution of ancillary protein strategyDyadic is well positioned to seize on geopolitical tailwinds driving reshoring/friendshoring of biomanufacturing supply chains to the United States and allies abroad JUPITER, Fla., June 02, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI) today announced a leadership change as part of its ongoing strategic shift to evolve into a revenue-generating provider of ancillary recombinant protein products supporting the life sciences, nutri

      6/2/25 8:35:00 AM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Dyadic Reports First Quarter 2025 Financial Results and Highlights of Recent Company Progress

      Expanded life science and industrial portfolio with six additional life science products in developmentAdvances toward commercialization of functional recombinant solutions for cell culture media, nucleic and industrial enzyme marketsUp to $4.5 million research grant awarded from the Coalition for Epidemic Preparedness (CEPI)Launched research for $3.0 million Gates Foundation grant for malaria and RSV antibody programsSelected to participate in the inaugural meeting of the "European Vaccines Hub for Pandemic Readiness (EVH)" project.Scientific Pre-Publication – "Expression and Characterization of SARS-CoV-2 Spike Protein in Thermothelomyces heterothallica C1"Cash, cash equivalents and invest

      5/14/25 4:05:00 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DYAI
    Leadership Updates

    Live Leadership Updates

    See more
    • Dyadic Appoints Doug Pace to Its Executive Leadership Team

      JUPITER, Fla., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet needs for effective, affordable and accessible biopharmaceutical products and alternative proteins for human and animal health, today announced the appointment of Doug Pace as Executive Vice President of Business Development. The expansion of Dyadic's management team is in response to the increased interest in the Company's microbial platforms, specifically the C1 technology for infectious disease and

      10/9/23 8:30:00 AM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Dyadic Appoints Chief Business Officer to Executive Leadership Team

      JUPITER, Fla., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines, therapeutics and other protein based products today announced the appointment of Joe Hazelton as Chief Business Officer, effective immediately. The creation of this role supports the global commercialization of the Company's new and existing business initiatives, including corporate strategy, business and corporate develo

      11/9/21 8:30:00 AM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DYAI
    Financials

    Live finance-specific insights

    See more
    • Dyadic Reports First Quarter 2025 Financial Results and Highlights of Recent Company Progress

      Expanded life science and industrial portfolio with six additional life science products in developmentAdvances toward commercialization of functional recombinant solutions for cell culture media, nucleic and industrial enzyme marketsUp to $4.5 million research grant awarded from the Coalition for Epidemic Preparedness (CEPI)Launched research for $3.0 million Gates Foundation grant for malaria and RSV antibody programsSelected to participate in the inaugural meeting of the "European Vaccines Hub for Pandemic Readiness (EVH)" project.Scientific Pre-Publication – "Expression and Characterization of SARS-CoV-2 Spike Protein in Thermothelomyces heterothallica C1"Cash, cash equivalents and invest

      5/14/25 4:05:00 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Dyadic to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025

      JUPITER, Fla., May 01, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as non-pharmaceutical applications including food, non-food and industrial applications, today announced that it will report its financial results for the first quarter 2025 and host a corporate update conference call on Wednesday, May 14, 2025. Conference Call Information Date: Wednesday, May 14, 2025 Time: 5:00 p.m. Eastern Time Dial-in numbers: Toll Free: +1-877-407-0784; International +1-201-689-8560

      5/1/25 3:00:00 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Dyadic Reports 2024 Year-End Financial Results and Business Updates

      Strong revenue performance, including approximately $1.9 million milestone and license revenue recognized in 2024Up to $7.5 million in grants awarded from CEPI and Gates Foundation intended to accelerate the C1 platform development timeline to manufacture vaccines and antibodies faster at a lower costGrowth in commercial pipelines with multiple products nearing market launch, including Human Serum Albumin and DNASe1Expanded alternative protein portfolio with six additional life science products in development for research, nutritional, and cell culture media applicationsContinued advancements in animal and human healthCash and investment-grade securities of $9.3 million as of December 31, 20

      3/26/25 4:05:00 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DYAI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Dyadic International Inc. (Amendment)

      SC 13G/A - DYADIC INTERNATIONAL INC (0001213809) (Subject)

      2/13/24 4:41:59 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Dyadic International Inc. (Amendment)

      SC 13G/A - DYADIC INTERNATIONAL INC (0001213809) (Subject)

      2/1/24 4:15:18 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Dyadic International Inc. (Amendment)

      SC 13G/A - DYADIC INTERNATIONAL INC (0001213809) (Subject)

      3/14/23 4:01:06 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care